What is DIPCAN?
DIPCAN is a study that takes a leap on personalized medicine thanks to the integration of clinical, genomic, anatomopathological and radiological data of 2,000 patients with non-hematologic metastatic tumors.
This is an observational study. Therefore, no treatment that would enhance the survival or quality of life of the patients will be provided. Only diagnostic tests will be performed. Eurofins Megalab coordinates the study and counts with the collaboration of different leading institutions in Spain such as the MD Anderson International Foundation Spain as the promoter of the study and Pangaea, Quibim, Genomcore, Atrys and Artelnics. It is a project that counts with the funding of the European Union through the Ministry of Economic Affairs and Digital Transformation.
DIPCAN was created in 2022 and will end in 2024. During this time, a set of diagnostic tests will be performed: analysis, magnetic resonance imaging, pathological anatomy and molecular and tumor expression analysis. The results of all these tests will be integrated with the aim to create an algorithm. The study will also consider two visits with the responsible oncologist apart from the tests.
· On the one hand, a visit will take place to get to know the medical story, explain the objectives and activities of the study and obtain the informed consent.
· On the other hand, another visit as closure to provide all the obtained results and answer all questions.
How can the DIPCAN study help you?
If you take part on the study as patient, you will have access to very specific tests that are very hard to access, like the molecular study. Once it is over, you will receive for free all the obtained results. The oncologist will explain to you all the findings on the results with detail and answer all your questions.
Through the integration of all the clinic, radiological, anatomopathological and molecular data obtained in the study, very valuable integrated information will be obtained. This information could provide a multidimensional knowledge about cancer in the Spanish population from all angles and could even translate into an advance in the treatment of patients with metastatic cancer.